Opinion: Biotech can — and must — reshape the pricing debate and protect future innovation
The week before the craziness known as J.P. Morgan 2020 began, more than 300 biotech and biopharma leaders signed onto the “New Commitment to Patients” published by STAT, promising to put patients first when it comes to treatment access and pricing comprised.
Aside from the sad irony that such a commitment needed to be stated at all, the open letter was a sign that at least some in the industry recognize that more public accountability on pricing is urgently needed.
